Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Antineoplastic Combined Chemotherapy Protocols"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 1170
Tytuł:
Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.
Autorzy:
Bahleda R; Drug Development Department, Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France.
Hollebecque A; Drug Development Department, Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France.
Varga A; Drug Development Department, Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France.
Gazzah A; Drug Development Department, Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France.
Massard C; Drug Development Department, Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France.
Deutsch E; Drug Development Department and Radiation Therapy Department, Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France.
Amellal N; Drug Development Department, Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France.
Farace F; Inserm Unit 981, Gustave Roussy, Villejuif Cedex, Paris, France.
Ould-Kaci M; Boehringer Ingelheim, 14 rue Jean Antoine de Baif, 75013 Paris, France.
Roux F; Boehringer Ingelheim, Reims, France.
Marzin K; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Soria JC; Drug Development Department, Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif Cedex, France.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Nov 17; Vol. 113 (10), pp. 1413-20. Date of Electronic Publication: 2015 Oct 29.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Carcinoma, Non-Small-Cell Lung/*drug therapy
Indoles/*administration & dosage
Lung Neoplasms/*drug therapy
Pancreatic Neoplasms/*drug therapy
Quinazolines/*administration & dosage
Adult ; Afatinib ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Drug Administration Schedule ; Female ; Humans ; Indoles/adverse effects ; Indoles/therapeutic use ; Male ; Maximum Tolerated Dose ; Middle Aged ; Quinazolines/adverse effects ; Quinazolines/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting.
Autorzy:
Lambrechts D; Vesalius Research Center, VIB, Leuven, Belgium.; Department of Oncology, Laboratory for Translational Genetics, KU Leuven, Leuven, Belgium.
Thienpont B; Vesalius Research Center, VIB, Leuven, Belgium.; Department of Oncology, Laboratory for Translational Genetics, KU Leuven, Leuven, Belgium.
Thuillier V; Department of Biostatistics, Sanofi, Chilly-Mazarin, France.
Sagaert X; Department of Pathology, KU Leuven, Leuven, Belgium.
Moisse M; Vesalius Research Center, VIB, Leuven, Belgium.; Department of Oncology, Laboratory for Translational Genetics, KU Leuven, Leuven, Belgium.
Peuteman G; Vesalius Research Center, VIB, Leuven, Belgium.; Department of Oncology, Laboratory for Translational Genetics, KU Leuven, Leuven, Belgium.
Pericay C; Hospital de Sabadell, Corporació Sanitaria Parc, Taulí-Institut Universitari, Sabadell, Barcelona, Spain.
Folprecht G; Universitätsklinikum Carl Gustav Carus, Dresden, Germany.
Zalcberg J; School of Public Health and Preventive Medicine, Monash University, Melbourne, USA.
Zilocchi C; Sanofi, Milan, Italy.
Margherini E; Sanofi, Oncology Division, Vitry-sur-Seine, France.
Chiron M; Translational and Experimental Medicine, Oncology, Sanofi, Vitry-sur-Seine, France.
Van Cutsem E; Digestive Oncology, University Hospitals Leuven and KU Leuven, Leuven, Belgium.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Sep 29; Vol. 113 (7), pp. 1027-34. Date of Electronic Publication: 2015 Sep 10.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Angiogenesis Inhibitors/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Biomarkers, Tumor/*blood
Colorectal Neoplasms/*drug therapy
Interleukin-8/*blood
Receptors, Vascular Endothelial Growth Factor/*administration & dosage
Recombinant Fusion Proteins/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor/genetics ; Colorectal Neoplasms/blood ; Colorectal Neoplasms/genetics ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/therapeutic use ; Humans ; Leucovorin/administration & dosage ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Mutation ; Neoplasm Metastasis ; Organoplatinum Compounds/administration & dosage ; Organoplatinum Compounds/therapeutic use ; Polymorphism, Single Nucleotide ; Receptors, Vascular Endothelial Growth Factor/adverse effects ; Recombinant Fusion Proteins/adverse effects ; Survival Analysis ; Treatment Outcome ; Vascular Endothelial Growth Factor B/genetics
SCR Protocol:
Folfox protocol
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours.
Autorzy:
Kerklaan BM; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Lolkema MP; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Devriese LA; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Voest EE; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Nol-Boekel A; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Mergui-Roelvink M; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Langenberg M; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Mykulowycz K; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Stoebenau J; GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
Lane S; GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
Legenne P; GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
Wissel P; GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
Smith DA; GlaxoSmithKline, Research Triangle Park, North Carolina, USA.
Giantonio BJ; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Schellens JH; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Science Faculty, Utrecht Institute of Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.
Witteveen PO; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Sep 01; Vol. 113 (5), pp. 706-15. Date of Electronic Publication: 2015 Aug 20.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Ovarian Neoplasms/*drug therapy
Pancreatic Neoplasms/*drug therapy
Administration, Oral ; Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/toxicity ; Female ; Humans ; Indazoles ; Male ; Maximum Tolerated Dose ; Middle Aged ; Ovarian Neoplasms/pathology ; Pancreatic Neoplasms/pathology ; Pyrimidines/administration & dosage ; Sulfonamides/administration & dosage ; Topotecan/administration & dosage ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.
Autorzy:
Macarulla T; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, P Vall d'Hebron 119-129, Barcelona 08035, Spain.
Cervantes A; Department of Haematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Avda Blasco Ibáñez 17, Valencia 46010, Spain.
Tabernero J; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, P Vall d'Hebron 119-129, Barcelona 08035, Spain.
Roselló S; Department of Haematology and Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Avda Blasco Ibáñez 17, Valencia 46010, Spain.
Van Cutsem E; Department of Gastroenterology, University Hospitals Gasthuisberg and KU Leuven, Herestraat 49, Leuven 3000, Belgium.
Tejpar S; Department of Gastroenterology, University Hospitals Gasthuisberg and KU Leuven, Herestraat 49, Leuven 3000, Belgium.
Prenen H; Department of Gastroenterology, University Hospitals Gasthuisberg and KU Leuven, Herestraat 49, Leuven 3000, Belgium.
Martinelli E; Department of Experimental and Clinical Medicine, Second University of Naples, Via S Pansini 5, Naples 80131, Italy.
Troiani T; Department of Experimental and Clinical Medicine, Second University of Naples, Via S Pansini 5, Naples 80131, Italy.
Laffranchi B; Merck Serono SA, 9 Chemin des Mines, Geneva 1202, Switzerland.
Jego V; Merck Serono SA, 9 Chemin des Mines, Geneva 1202, Switzerland.
von Richter O; Merck KGaA, Frankfurter Strasse 250, F131/102, Darmstadt 64293, Germany.
Ciardiello F; Department of Experimental and Clinical Medicine, Second University of Naples, Via S Pansini 5, Naples 80131, Italy.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Jun 09; Vol. 112 (12), pp. 1874-81. Date of Electronic Publication: 2015 May 19.
Typ publikacji:
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Colorectal Neoplasms/*drug therapy
Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Camptothecin/pharmacokinetics ; Colorectal Neoplasms/enzymology ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/pharmacokinetics ; Genes, ras ; Humans ; Leucovorin/administration & dosage ; Leucovorin/pharmacokinetics ; Male ; Middle Aged ; Mutation ; Neoplasm Metastasis ; Niacinamide/administration & dosage ; Niacinamide/analogs & derivatives ; Niacinamide/pharmacokinetics ; Proto-Oncogene Proteins/genetics ; Proto-Oncogene Proteins p21(ras) ; Treatment Outcome ; ras Proteins/genetics
SCR Protocol:
IFL protocol
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer.
Autorzy:
Lim SH; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Kim TW; Division of Hematology-Oncology, Department of Medicine, Asan Medical Center, Seoul, South Korea.
Hong YS; Division of Hematology-Oncology, Department of Medicine, Asan Medical Center, Seoul, South Korea.
Han SW; Division of Hematology-Oncology, Department of Medicine, Seoul National University Hospital, Seoul, South Korea.
Lee KH; Division of Hematology-Oncology, Department of Medicine, Seoul National University Hospital, Seoul, South Korea.
Kang HJ; Division of Hematology-Oncology, Department of Medicine, Korea Cancer Center Hospital, Seoul, South Korea.
Hwang IG; Division of Hematology-Oncology, Department of Medicine, Chungang University Hospital, Seoul, South Korea.
Lee JY; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Kim HS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Kim ST; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Lee J; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Park JO; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Park SH; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Park YS; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Lim HY; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Jung SH; Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Kang WK; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Nov 17; Vol. 113 (10), pp. 1421-6. Date of Electronic Publication: 2015 Oct 27.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Colorectal Neoplasms/*drug therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage
Simvastatin/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Camptothecin/therapeutic use ; Capecitabine/administration & dosage ; Capecitabine/therapeutic use ; Double-Blind Method ; Drug Administration Schedule ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/therapeutic use ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Irinotecan ; Leucovorin/administration & dosage ; Leucovorin/therapeutic use ; Male ; Middle Aged ; Neoplasm Metastasis ; Republic of Korea ; Simvastatin/adverse effects ; Simvastatin/therapeutic use ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.
Autorzy:
Portal A; Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Descartes University, Paris, France.
Pernot S; Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Descartes University, Paris, France.
Tougeron D; Department of Gastroenterology, Poitiers University Hospital, Poitiers, France.
Arbaud C; Methodological and Quality of Life Unit in Oncology, Quality of Life and Cancer Clinical Research Platform, Besançon University Hospital, Besançon, France.
Bidault AT; Department of Gastroenterology, Kremlin Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Sud University, Le Kremlin Bicêtre, France.
de la Fouchardière C; Department of Medical Oncology, Anticancer Center Leon Berard, Lyon I university, Lyon, France.
Hammel P; Department of Digestive Oncology, Hospital Beaujon, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Denis Diderot University, Clichy, France.
Lecomte T; Department of Hepato-Gastroenterology and Digestive Oncology, University Hospital of Tours, UMR CNRS 7192, François-Rabelais University, Tours, France.
Dréanic J; Gastroenterology and Endoscopy Unit, Cochin Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Descartes University, Sorbonne Paris Cité, Paris, France.
Coriat R; Gastroenterology and Endoscopy Unit, Cochin Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Descartes University, Sorbonne Paris Cité, Paris, France.
Bachet JB; Department of Gastroenterology, La Pitié-Salpétrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, UPMC University Paris 06, Paris, France.
Dubreuil O; Department of Gastroenterology, La Pitié-Salpétrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne University, UPMC University Paris 06, Paris, France.
Marthey L; Department of Hepatogastroenterology and Nutrition, Antoine-Béclère Hospital, Assistance publique-Hôpitaux de Paris (AP-HP), DHU Hepatinov, Clamart, France.
Dahan L; Department of Gastroenterology, University Hospital La Timone, Aix-Marseille University, Marseille, France.
Tchoundjeu B; Department of Gastroenterology and Digestive Oncology, Orleans Regional Hospital (CHRO), Orleans, France.
Locher C; Department of Gastroenterology, Meaux Hospital, Meaux, France.
Lepère C; Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Descartes University, Paris, France.
Bonnetain F; Methodological and Quality of Life Unit in Oncology, Quality of Life and Cancer Clinical Research Platform, Besançon University Hospital, Besançon, France.
Taieb J; Department of Gastroenterology and Digestive Oncology, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris Descartes University, Paris, France.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Sep 29; Vol. 113 (7), pp. 989-95. Date of Electronic Publication: 2015 Sep 15.
Typ publikacji:
Clinical Study; Journal Article; Multicenter Study
MeSH Terms:
Adenocarcinoma/*drug therapy
Albumins/*administration & dosage
Antineoplastic Agents/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Deoxycytidine/*analogs & derivatives
Paclitaxel/*administration & dosage
Pancreatic Neoplasms/*drug therapy
Adenocarcinoma/pathology ; Adult ; Aged ; Aged, 80 and over ; Albumins/adverse effects ; Antineoplastic Agents/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Paclitaxel/adverse effects ; Pancreatic Neoplasms/pathology ; Prospective Studies ; Survival Analysis ; Treatment Outcome ; Gemcitabine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Upfront FOLFOXIRI+bevacizumab followed by fluoropyrimidin and bevacizumab maintenance in patients with molecularly unselected metastatic colorectal cancer.
Autorzy:
Stein A; University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany.
Atanackovic D; University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany.
Hildebrandt B; Charité Universitätsmedizin Berlin, Campus Charité Mitte, Charitéplatz 1, Berlin 10117, Germany.
Stübs P; University Hospital Magdeburg, Leipziger Strasse 44, Magdeburg 39120, Germany.
Brugger W; Schwarzwald-Baar Klinikum, Klinikstrasse 11, Villingen-Schwenningen 78052, Germany.
Hapke G; Marienkrankenhaus, Alfredstrasse 9, Hamburg 22087, Germany.
Steffens CC; MVZ Hämatologie/Onkologie Klinik Dr Hancken, Harsefelder Str. 8, Stade 21680, Germany.
Illerhaus G; Klinikum Stuttgart, Kriegsbergstraße 60, Stuttgart 70174, Germany.
Bluemner E; Ecron Acunova GmbH, Hahnstrasse 70, Frankfurt 60528, Germany.
Stöhlmacher J; Tumorgenetik Bonn, Maximilianstrasse 28d, Bonn 53111, Germany.
Bokemeyer C; University Medical Centre Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Sep 15; Vol. 113 (6), pp. 872-7. Date of Electronic Publication: 2015 Sep 03.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Angiogenesis Inhibitors/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Bevacizumab/*administration & dosage
Colorectal Neoplasms/*drug therapy
Adult ; Aged ; Angiogenesis Inhibitors/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bevacizumab/adverse effects ; Camptothecin/administration & dosage ; Camptothecin/adverse effects ; Camptothecin/analogs & derivatives ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/mortality ; Disease-Free Survival ; Feasibility Studies ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/adverse effects ; Genes, ras ; Humans ; Induction Chemotherapy/methods ; Irinotecan ; Leucovorin/administration & dosage ; Leucovorin/adverse effects ; Maintenance Chemotherapy/methods ; Male ; Middle Aged ; Organoplatinum Compounds/administration & dosage ; Organoplatinum Compounds/adverse effects ; Oxaliplatin ; Severity of Illness Index
SCR Protocol:
FOLFOXIRI protocol
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas.
Autorzy:
Eroglu Z; City of Hope National Medical Center, Duarte, CA, USA.
Tawbi HA; University of Pittsburgh Cancer Institute and University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Hu J; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
Guan M; City of Hope National Medical Center, Duarte, CA, USA.
Frankel PH; City of Hope National Medical Center, Duarte, CA, USA.
Ruel NH; City of Hope National Medical Center, Duarte, CA, USA.
Wilczynski S; City of Hope National Medical Center, Duarte, CA, USA.
Christensen S; University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Gandara DR; University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Chow WA; City of Hope National Medical Center, Duarte, CA, USA.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 May 12; Vol. 112 (10), pp. 1644-51. Date of Electronic Publication: 2015 Apr 21.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Sarcoma/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Benzimidazoles/administration & dosage ; Benzimidazoles/adverse effects ; Disease-Free Survival ; Drug Administration Schedule ; Female ; Humans ; Male ; Middle Aged ; Sirolimus/administration & dosage ; Sirolimus/adverse effects ; Sirolimus/analogs & derivatives ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.
Autorzy:
Sakiyama T; Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan.
Tsurutani J; Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan.
Iwasa T; Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan.
Kawakami H; Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan.
Nonagase Y; Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan.
Yoshida T; Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan.
Tanaka K; Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan.
Fujisaka Y; Clinical Research Center, Osaka Medical Collage Hospital, 2-7 Daigaku-cho, Takatsuki 569-8686, Japan.
Kurata T; Department of Thoracic Oncology, Kansai Medical University Hirakata Hospital, 2-3-1 Shinmachi, Hirakata 573-1191, Japan.
Komoike Y; Department of Surgery, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan.
Nishio K; Department of Genome Biology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan.
Nakagawa K; Department of Medical Oncology, Kindai University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-sayama 589-8511, Japan.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Mar 03; Vol. 112 (5), pp. 819-24. Date of Electronic Publication: 2015 Feb 05.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Breast Neoplasms/*drug therapy
Furans/*administration & dosage
Furans/*pharmacokinetics
Ketones/*administration & dosage
Ketones/*pharmacokinetics
Oxonic Acid/*administration & dosage
Oxonic Acid/*pharmacokinetics
Tegafur/*administration & dosage
Tegafur/*pharmacokinetics
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Combinations ; Female ; Furans/therapeutic use ; Humans ; Ketones/therapeutic use ; Maximum Tolerated Dose ; Middle Aged ; Neoplasm Metastasis/drug therapy ; Oxonic Acid/therapeutic use ; Tegafur/therapeutic use ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer.
Autorzy:
Bazzola L; U.O.di Patologia Mammaria-Breast Cancer Unit, U.S. Terapia Molecolare e Farmacogenomica, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
Foroni C; U.O.di Patologia Mammaria-Breast Cancer Unit, U.S. Terapia Molecolare e Farmacogenomica, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
Andreis D; U.O.di Patologia Mammaria-Breast Cancer Unit, U.S. Terapia Molecolare e Farmacogenomica, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
Zanoni V; U.O.di Patologia Mammaria-Breast Cancer Unit, U.S. Terapia Molecolare e Farmacogenomica, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
R Cappelletti M; U.O.di Patologia Mammaria-Breast Cancer Unit, U.S. Terapia Molecolare e Farmacogenomica, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
Allevi G; U.O.di Patologia Mammaria-Breast Cancer Unit, U.S. Terapia Molecolare e Farmacogenomica, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
Aguggini S; U.O.di Patologia Mammaria-Breast Cancer Unit, U.S. Terapia Molecolare e Farmacogenomica, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
Strina C; U.O.di Patologia Mammaria-Breast Cancer Unit, U.S. Terapia Molecolare e Farmacogenomica, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
Milani M; U.O.di Patologia Mammaria-Breast Cancer Unit, U.S. Terapia Molecolare e Farmacogenomica, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
Venturini S; U.O.di Patologia Mammaria-Breast Cancer Unit, U.S. Terapia Molecolare e Farmacogenomica, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
Ferrozzi F; U.O. Diagnostica per Immagini-Figlie di San Camillo-Via F Filzi 56, Cremona, Italy.
Giardini R; U.O. di Anatomia Patologica, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
Bertoni R; U.O. di Anatomia Patologica, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
Turley H; CRUK Tumor Pathology Group, Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford OX3 9DS, UK.
Gatter K; CRUK Tumor Pathology Group, Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford OX3 9DS, UK.
Petronini PG; Dipartimento di Medicina Sperimentale, Via Volturno, 39, 43100 Parma, Italy.
Fox SB; Peter MacCallum Cancer Centre, St Andrews Place, East Melbourne, Victoria 3002, Australia.
Harris AL; Weatherall Molecular Oncology Laboratories, Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.
Martinotti M; U.O. Chirurgia Generale, Dipartimento di Chirurgia, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
Berruti A; U.O. Chirurgia Generale, Dipartimento di Chirurgia, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
Bottini A; U.O.di Patologia Mammaria-Breast Cancer Unit, U.S. Terapia Molecolare e Farmacogenomica, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
Reynolds AR; Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London SW3 6JB, UK.
Generali D; U.O.di Patologia Mammaria-Breast Cancer Unit, U.S. Terapia Molecolare e Farmacogenomica, Azienda Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Jan 06; Vol. 112 (1), pp. 52-60. Date of Electronic Publication: 2014 Dec 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Breast Neoplasms/*drug therapy
Administration, Metronomic ; Aged ; Antineoplastic Agents/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/metabolism ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Cyclophosphamide/pharmacokinetics ; Female ; Humans ; Letrozole ; Middle Aged ; Niacinamide/administration & dosage ; Niacinamide/adverse effects ; Niacinamide/analogs & derivatives ; Niacinamide/pharmacokinetics ; Nitriles/administration & dosage ; Nitriles/adverse effects ; Nitriles/pharmacokinetics ; Phenylurea Compounds/administration & dosage ; Phenylurea Compounds/adverse effects ; Phenylurea Compounds/pharmacokinetics ; Randomized Controlled Trials as Topic ; Sorafenib ; Triazoles/administration & dosage ; Triazoles/adverse effects ; Triazoles/pharmacokinetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.
Autorzy:
Wilky BA; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA.
Rudek MA; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA.
Ahmed S; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA.
Laheru DA; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA.
Cosgrove D; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA.
Donehower RC; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA.
Nelkin B; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA.
Ball D; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA.
Doyle LA; National Cancer Institute, 9609 Medical Center Drive, MSC 9379, Bethesda, MD 20892, USA.
Chen H; National Cancer Institute, 9609 Medical Center Drive, MSC 9379, Bethesda, MD 20892, USA.
Ye X; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA.
Bigley G; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Maccelsfield, Cheshire SK104TG, UK.
Womack C; Oncology iMed, AstraZeneca, Mereside, Alderley Park, Maccelsfield, Cheshire SK104TG, UK.
Azad NS; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Jan 06; Vol. 112 (1), pp. 24-31. Date of Electronic Publication: 2014 Sep 30.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Neoplasms/*drug therapy
Aged ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/pharmacokinetics ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Benzimidazoles/administration & dosage ; Benzimidazoles/adverse effects ; Benzimidazoles/pharmacokinetics ; Cohort Studies ; Disease-Free Survival ; Female ; Humans ; MAP Kinase Kinase Kinases/antagonists & inhibitors ; Male ; Middle Aged ; Neoplasms/metabolism ; Receptor, IGF Type 1/antagonists & inhibitors ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer.
Autorzy:
Kang YK; Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro, 43-gil, Songpa-gu, Seoul 138-736, Korea.
Rha SY; Yonsei Cancer Center, Yonsei Cancer Research Institute, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea.
Tassone P; Medical Oncology Unit, Magna Graecia University, Viale Europa, 88100 Catanzaro, Italy.
Barriuso J; Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain.
Yu R; Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
Szado T; Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
Garg A; Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
Bang YJ; Seoul National University College of Medicine, 01 Daehak-ro, Jongno-gu, Seoul 110-744, Korea.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2014 Aug 12; Vol. 111 (4), pp. 660-6. Date of Electronic Publication: 2014 Jun 24.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Adenocarcinoma/*drug therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Stomach Neoplasms/*drug therapy
Adenocarcinoma/metabolism ; Adenocarcinoma/pathology ; Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Capecitabine ; Cisplatin/administration & dosage ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Diarrhea/chemically induced ; Female ; Fluorouracil/administration & dosage ; Fluorouracil/analogs & derivatives ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Receptor, ErbB-2/metabolism ; Stomach Neoplasms/metabolism ; Stomach Neoplasms/pathology ; Trastuzumab ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.
Autorzy:
Del Conte G; Department of Medical Oncology, Ospedale San Raffaele Scientific Institute, Milan, Italy.
Sessa C; 1] Department of Medical Oncology, Ospedale San Raffaele Scientific Institute, Milan, Italy [2] Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona Hospital, Bellinzona, Switzerland.
von Moos R; Kantonsspital Graubünden, Chur, Switzerland.
Viganò L; Department of Medical Oncology, Ospedale San Raffaele Scientific Institute, Milan, Italy.
Digena T; Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona Hospital, Bellinzona, Switzerland.
Locatelli A; Department of Medical Oncology, Ospedale San Raffaele Scientific Institute, Milan, Italy.
Gallerani E; Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona Hospital, Bellinzona, Switzerland.
Fasolo A; Department of Medical Oncology, Ospedale San Raffaele Scientific Institute, Milan, Italy.
Tessari A; Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Cathomas R; Kantonsspital Graubünden, Chur, Switzerland.
Gianni L; Department of Medical Oncology, Ospedale San Raffaele Scientific Institute, Milan, Italy.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2014 Aug 12; Vol. 111 (4), pp. 651-9. Date of Electronic Publication: 2014 Jul 15.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Breast Neoplasms/*drug therapy
Ovarian Neoplasms/*drug therapy
Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Breast Neoplasms/metabolism ; DNA Damage ; Doxorubicin/administration & dosage ; Doxorubicin/analogs & derivatives ; Female ; Histones/metabolism ; Humans ; Male ; Maximum Tolerated Dose ; Middle Aged ; Ovarian Neoplasms/metabolism ; Phthalazines/administration & dosage ; Piperazines/administration & dosage ; Polyethylene Glycols/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.
Autorzy:
Patnaik A; Clinical Research, South Texas Accelerated Research Therapeutics (START), 4383 Medical Drive, San Antonio, TX 78229, USA.
Weiss GJ; Division of Hematology and Medical Oncology, Virginia G Piper Cancer Center, 10460 North 92nd Street, Suite 101, Scottsdale, AZ 85258, USA.
Papadopoulos KP; Clinical Research, South Texas Accelerated Research Therapeutics (START), 4383 Medical Drive, San Antonio, TX 78229, USA.
Hofmeister CC; Hematology Division Internal Medicine Department, Ohio State University, 320 West 10th Avenue, Columbus, OH 43210, USA.
Tibes R; Division of Hematology and Medical Oncology, Virginia G Piper Cancer Center, 10460 North 92nd Street, Suite 101, Scottsdale, AZ 85258, USA.
Tolcher A; Clinical Research, South Texas Accelerated Research Therapeutics (START), 4383 Medical Drive, San Antonio, TX 78229, USA.
Isaacs R; Merck, 2000 Galloping Hill Road, Kenilworth, NJ 07033, USA.
Jac J; AVEO Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA 02139, USA.
Han M; AVEO Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA 02139, USA.
Payumo FC; AVEO Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA 02139, USA.
Cotreau MM; AVEO Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, MA 02139, USA.
Ramanathan RK; Division of Hematology and Medical Oncology, Virginia G Piper Cancer Center, 10460 North 92nd Street, Suite 101, Scottsdale, AZ 85258, USA.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2014 Jul 15; Vol. 111 (2), pp. 272-80. Date of Electronic Publication: 2014 Jun 05.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Multiple Myeloma/*drug therapy
Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Cohort Studies ; Erlotinib Hydrochloride ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/metabolism ; Multiple Myeloma/pathology ; Neoplasms/metabolism ; Neoplasms/pathology ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/pharmacokinetics ; Quinazolines/administration & dosage ; Quinazolines/adverse effects ; Quinazolines/pharmacokinetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
Autorzy:
Tan AR; Rutgers Cancer Institute of New Jersey,195 Little Albany Street, New Brunswick, NJ 08903, USA.
Dowlati A; University Hospitals Case Medical Center, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH 44106, USA.
Stein MN; Rutgers Cancer Institute of New Jersey,195 Little Albany Street, New Brunswick, NJ 08903, USA.
Jones SF; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 3322 West End Avenue, Nashville, TN 37203, USA.
Infante JR; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 3322 West End Avenue, Nashville, TN 37203, USA.
Bendell J; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 3322 West End Avenue, Nashville, TN 37203, USA.
Kane MP; Rutgers Cancer Institute of New Jersey,195 Little Albany Street, New Brunswick, NJ 08903, USA.
Levinson KT; Rutgers Cancer Institute of New Jersey,195 Little Albany Street, New Brunswick, NJ 08903, USA.
Suttle AB; GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709, USA.
Burris HA 3rd; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, 3322 West End Avenue, Nashville, TN 37203, USA.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2014 May 27; Vol. 110 (11), pp. 2647-54. Date of Electronic Publication: 2014 May 06.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Biliary Tract Neoplasms/*drug therapy
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Salivary Gland Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/toxicity ; Drug Administration Schedule ; Female ; Humans ; Indazoles ; Lapatinib ; Male ; Maximum Tolerated Dose ; Middle Aged ; Paclitaxel/administration & dosage ; Pyrimidines/administration & dosage ; Quinazolines/administration & dosage ; Sulfonamides/administration & dosage ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
Autorzy:
Hottinger AF; 1] Clinical Research Unit of the Foundation Dr Henri Dubois Ferriére Dinu Lipatti & Centre of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland [2] Department of Clinical Neurosciences & Oncology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland.
Ben Aissa A; Clinical Research Unit of the Foundation Dr Henri Dubois Ferriére Dinu Lipatti & Centre of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Espeli V; Clinical Research Unit of the Foundation Dr Henri Dubois Ferriére Dinu Lipatti & Centre of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Squiban D; Clinical Research Unit of the Foundation Dr Henri Dubois Ferriére Dinu Lipatti & Centre of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Dunkel N; Clinical Research Unit of the Foundation Dr Henri Dubois Ferriére Dinu Lipatti & Centre of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Vargas MI; Department of Neuroradiology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Hundsberger T; Department of Neurology and hematology/oncology, Cantonal Hospital St Gallen, St Gallen, Switzerland.
Mach N; Clinical Research Unit of the Foundation Dr Henri Dubois Ferriére Dinu Lipatti & Centre of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Schaller K; Department of Neurosurgery Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Weber DC; 1] Clinical Research Unit of the Foundation Dr Henri Dubois Ferriére Dinu Lipatti & Centre of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland [2] Department of Radio-oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Bodmer A; Clinical Research Unit of the Foundation Dr Henri Dubois Ferriére Dinu Lipatti & Centre of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Dietrich PY; Clinical Research Unit of the Foundation Dr Henri Dubois Ferriére Dinu Lipatti & Centre of Oncology, Geneva University Hospitals and University of Geneva, Geneva, Switzerland.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2014 May 27; Vol. 110 (11), pp. 2655-61. Date of Electronic Publication: 2014 May 01.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Brain Neoplasms/*therapy
Glioblastoma/*therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Antineoplastic Combined Chemotherapy Protocols/toxicity ; Brain Neoplasms/mortality ; Chemoradiotherapy ; Dacarbazine/administration & dosage ; Dacarbazine/analogs & derivatives ; Disease-Free Survival ; Female ; Glioblastoma/mortality ; Humans ; Male ; Maximum Tolerated Dose ; Middle Aged ; Niacinamide/administration & dosage ; Niacinamide/analogs & derivatives ; Phenylurea Compounds/administration & dosage ; Sorafenib ; Temozolomide ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial.
Autorzy:
Algazi AP; Department of Medicine, Division of Hematology/Oncology, University of California, 1600 Divisadero St MTZ-A741, San Francisco, CA 94143-1770, USA.
Cha E; Department of Medicine, Division of Hematology/Oncology, University of California, 1600 Divisadero St MTZ-A741, San Francisco, CA 94143-1770, USA.
Ortiz-Urda SM; Department of Dermatology, University of California, 1600 Divisadero St MTZ-A741, San Francisco, CA 94143-1770, USA.
McCalmont T; Department of Dermatology, University of California, 1600 Divisadero St MTZ-A741, San Francisco, CA 94143-1770, USA.
Bastian BC; Department of Dermatology, University of California, 1600 Divisadero St MTZ-A741, San Francisco, CA 94143-1770, USA.
Hwang J; Department of Medicine, Division of Hematology/Oncology, University of California, 1600 Divisadero St MTZ-A741, San Francisco, CA 94143-1770, USA.
Pampaloni MH; Department of Nuclear Medicine, University of California, 1600 Divisadero St MTZ-A741, San Francisco, CA 94143-1770, USA.
Behr S; Department of Nuclear Medicine, University of California, 1600 Divisadero St MTZ-A741, San Francisco, CA 94143-1770, USA.
Chong K; Department of Dermatology, University of California, 1600 Divisadero St MTZ-A741, San Francisco, CA 94143-1770, USA.
Cortez B; Department of Medicine, Division of Hematology/Oncology, University of California, 1600 Divisadero St MTZ-A741, San Francisco, CA 94143-1770, USA.
Quiroz A; Department of Medicine, Division of Hematology/Oncology, University of California, 1600 Divisadero St MTZ-A741, San Francisco, CA 94143-1770, USA.
Coakley F; Department of Radiology, University of California, 1600 Divisadero St MTZ-A741, San Francisco, CA 94143-1770, USA.
Liu S; Department of Radiology, University of California, 1600 Divisadero St MTZ-A741, San Francisco, CA 94143-1770, USA.
Daud AI; Department of Medicine, Division of Hematology/Oncology, University of California, 1600 Divisadero St MTZ-A741, San Francisco, CA 94143-1770, USA.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Apr 14; Vol. 112 (8), pp. 1326-31. Date of Electronic Publication: 2015 Mar 31.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Imidazoles/*administration & dosage
Indazoles/*administration & dosage
Melanoma/*drug therapy
Protein Kinase Inhibitors/*administration & dosage
Proto-Oncogene Proteins B-raf/*genetics
Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Axitinib ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Dideoxynucleosides ; Female ; Humans ; Imidazoles/adverse effects ; Indazoles/adverse effects ; Male ; Melanoma/diagnostic imaging ; Melanoma/genetics ; Middle Aged ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Positron-Emission Tomography/methods ; Prospective Studies ; Protein Kinase Inhibitors/adverse effects ; Radiography ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer.
Autorzy:
Gharaibeh M; Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA.
McBride A; Arizona Cancer Center, University of Arizona, Tucson, AZ 85721, USA.
Bootman JL; Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA.
Abraham I; 1] Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona, Tucson, AZ 85721, USA [2] Arizona Cancer Center, University of Arizona, Tucson, AZ 85721, USA.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Apr 14; Vol. 112 (8), pp. 1301-5. Date of Electronic Publication: 2015 Mar 19.
Typ publikacji:
Journal Article
MeSH Terms:
Antimetabolites, Antineoplastic/*economics
Antineoplastic Combined Chemotherapy Protocols/*economics
Deoxycytidine/*analogs & derivatives
Pancreatic Neoplasms/*drug therapy
Adult ; Albumins/administration & dosage ; Albumins/economics ; Antimetabolites, Antineoplastic/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cost-Benefit Analysis ; Deoxycytidine/administration & dosage ; Deoxycytidine/economics ; Humans ; Markov Chains ; Middle Aged ; Models, Economic ; Neoplasm Metastasis ; Paclitaxel/administration & dosage ; Paclitaxel/economics ; Pancreatic Neoplasms/economics ; Quality-Adjusted Life Years ; Survival Analysis ; United Kingdom ; Gemcitabine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer.
Autorzy:
Péron J; 1] Service de biostatistiques, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite F-69310, France [2] CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Université Lyon 1, Villeurbanne, France.
Roy P; 1] Service de biostatistiques, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite F-69310, France [2] CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Université Lyon 1, Villeurbanne, France.
Ding K; NCIC Clinical Trials Group, Queen's University, Kingston, Ontario, Canada.
Parulekar WR; NCIC Clinical Trials Group, Queen's University, Kingston, Ontario, Canada.
Roche L; 1] Service de biostatistiques, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite F-69310, France [2] CNRS, UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Université Lyon 1, Villeurbanne, France.
Buyse M; International Drug Development Institute (IDDI), Louvain-la-Neuve, Belgium.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Mar 17; Vol. 112 (6), pp. 971-6. Date of Electronic Publication: 2015 Mar 17.
Typ publikacji:
Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Pancreatic Neoplasms/*drug therapy
Analgesics/administration & dosage ; Analgesics/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Deoxycytidine/administration & dosage ; Deoxycytidine/adverse effects ; Deoxycytidine/analogs & derivatives ; Disease-Free Survival ; Erlotinib Hydrochloride ; Humans ; Pancreatic Neoplasms/mortality ; Protein Kinase Inhibitors/administration & dosage ; Protein Kinase Inhibitors/adverse effects ; Quinazolines/administration & dosage ; Quinazolines/adverse effects ; Risk Assessment ; Treatment Outcome ; Gemcitabine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Phase II study of pemetrexed in combination with cisplatin in patients with advanced urothelial cancer: the PECULIAR study (KCSG 10-17).
Autorzy:
Choi YJ; 1] Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea [2] Division of Hemato-oncology, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Republic of Korea.
Lee SH; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
Lee JL; 1] Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea [2] Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Ahn JH; 1] Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea [2] Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Lee KH; Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
You D; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Hong B; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Hong JH; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Ahn H; Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
British journal of cancer [Br J Cancer] 2015 Jan 20; Vol. 112 (2), pp. 260-5. Date of Electronic Publication: 2014 Nov 27.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Transitional Cell/*drug therapy
Lung Neoplasms/*drug therapy
Urinary Bladder Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Transitional Cell/mortality ; Carcinoma, Transitional Cell/secondary ; Cisplatin/administration & dosage ; Disease-Free Survival ; Female ; Glutamates/administration & dosage ; Guanine/administration & dosage ; Guanine/analogs & derivatives ; Humans ; Kaplan-Meier Estimate ; Lung Neoplasms/mortality ; Lung Neoplasms/secondary ; Male ; Middle Aged ; Pemetrexed ; Treatment Outcome ; Urinary Bladder Neoplasms/mortality ; Urinary Bladder Neoplasms/pathology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Wyświetlanie 1-20 z 1170

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies